Merck Homes In On Defect Claims In Fosamax Closing

Law360, New York (June 24, 2010, 7:38 PM EDT) -- In closing arguments Thursday, a lawyer for Merck & Co. sought to boil down Shirley Boles' case over jaw bone death allegedly associated with Fosamax to one central question: whether the osteoporosis drug is actually defective.

Paul F. Strain of Venable LLP began his remarks in the U.S. District Court for the Southern District of New York by telling the jurors that their work would be over if they simply answered the design defect question in the negative.

That should be an easy choice based on...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.